Jiangsu Hengrui Pharmaceuticals Co., Ltd. has received approval from China’s National Medical Products Administration (NMPA) for INS068 (insulin shudi), a once-daily, long-acting insulin analog, in adults with type 2 diabetes mellitus (T2DM).
The decision was announced on July 29, 2026. The drug has been classified as a Category 1 new chemical entity by Chinese regulators, and is described by Jiangsu Hengrui Pharmaceuticals Co., Ltd. as the first domestically developed long-acting insulin analog to reach the Chinese market.
Mechanism and Design
INS068 is a novel soluble long-acting insulin analog built on desB30 human insulin, with a modification introduced at the B29 lysine side chain. According to Jiangsu Hengrui Pharmaceuticals Co., Ltd. , the molecule has a half-life of approximately 21 hours in humans. In euglycemic clamp studies at steady state, the company reported that the glucose-lowering effect was sustained for more than 42 hours.
The drug is administered as a once-daily subcutaneous injection.
Phase III Data
The approval is supported by two randomized, open-label, parallel-group Phase III trials in which INS068 was compared head-to-head with insulin glargine:
INS068-301 enrolled adults with T2DM whose blood glucose was inadequately controlled on basal insulin. Over 26 weeks of treatment, INS068 reduced HbA1c by 0.70% from baseline, compared with a 0.83% reduction in the glargine arm (between-group difference: 0.13%; 95% CI -0.05 to 0.31), meeting the pre-specified non-inferiority criterion.

Fig.1.Primary Endpoint of Study INS068-301: Change in HbA1c from Baseline at Week 26 of Treatment
INS068-302 enrolled adults with T2DM inadequately controlled on oral antidiabetic drugs. Over 26 weeks, HbA1c dropped by 1.34% in the INS068 group and 1.36% in the glargine group (between-group difference: 0.02%; 95% CI -0.14% to 0.18%), again meeting non-inferiority. Fasting plasma glucose (FPG) decreased by 3.35 mmol/L with INS068 and 3.21 mmol/L with glargine. Glycemic reductions were maintained through 52 weeks of treatment, with comparable efficacy between arms.
Fig.2.Primary endpoint of Study INS068-302: change in HbA1c from baseline
In both studies, INS068 was associated with a lower rate of hypoglycemia than insulin glargine, according to the company.
Regulatory and Market Context
Data from the INS068 program were first presented at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) in September 2025. As a Category 1 new drug approved in China, INS068 has not been previously approved in any other jurisdiction, and its regulatory pathway outside of China has not been disclosed.
Source: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceuticals; National Medical Products Administration; 61st EASD Annual Meeting, September 2025.